Metsera soars on Pfizer's $4.9 billion buyout deal
Shares of obesity drug developer Metsera MTSR.O jump 56.3% to $52.08 premarket
Pfizer PFE.N says it will buy Metsera in a deal valued at $4.9 billion
PFE will pay MTSR for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones
The $47.50 per share deal represents a 42.6% premium over MTSR's Friday closing price of $33.32
*The deal is expected to close in fourth quarter of 2025
PFE shares up 2.8% premarket
Up to last close, MTSR stock up ~85%, PFE down 9% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








